p27(Kip1) is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients.
(2010) In International Journal of Cancer Apr 7. p.2851-2858- Abstract
- The cell cycle regulating protein p27(Kip1) (p27) has dual roles by acting as both a cdk-inhibitor and as an assembly factor for different cdk-complexes. Loss of p27 has been linked to malignant features in tumours, however the exact role of p27 deregulation in breast cancer regarding prognostic and treatment predictive information has not been fully clarified. We have evaluated p27 expression in 328 primary, stage II breast cancers from premenopausal patients who had been randomised to either tamoxifen treatment or no adjuvant treatment after surgery. p27 was associated with the oestrogen receptor (ER) and cyclin D1, and p27 downregulation was associated with high proliferation. There was no association between recurrence-free-survival... (More)
- The cell cycle regulating protein p27(Kip1) (p27) has dual roles by acting as both a cdk-inhibitor and as an assembly factor for different cdk-complexes. Loss of p27 has been linked to malignant features in tumours, however the exact role of p27 deregulation in breast cancer regarding prognostic and treatment predictive information has not been fully clarified. We have evaluated p27 expression in 328 primary, stage II breast cancers from premenopausal patients who had been randomised to either tamoxifen treatment or no adjuvant treatment after surgery. p27 was associated with the oestrogen receptor (ER) and cyclin D1, and p27 downregulation was associated with high proliferation. There was no association between recurrence-free-survival (RFS) and p27 (HR=0.800, 95%CI 0.523-1.222, p=0.300), indicating that p27 is not a prognostic marker. The predictive value of p27 was analysed by comparing RFS in tamoxifen treated and untreated patients in subgroups of low and high p27 expression (HR=0.747, 95%CI 0.335-1.664, p=0.474 and HR=0.401, 95%CI 0.240-0.670, p<0.001, respectively). Only patients with p27 high tumours benefited from tamoxifen (multivariate interaction analysis p=0.034). Our study suggests that p27 downregulation is associated with tamoxifen resistance in premenopausal breast cancer but is not linked to impaired prognosis. (c) 2010 UICC. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1582554
- author
- Stendahl, Maria LU ; Björner, Sofie LU ; Wigerup, Caroline LU ; Jirström, Karin LU ; Jönsson, Per-Ebbe LU ; Stål, Olle and Landberg, Göran LU
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- in
- International Journal of Cancer
- volume
- Apr 7
- pages
- 2851 - 2858
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- wos:000284208400012
- pmid:20201092
- scopus:78249249610
- pmid:21351264
- ISSN
- 0020-7136
- DOI
- 10.1002/ijc.25297
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Pathology (Malmö) (013031000), Surgery Research Unit (013242220), Pathology, (Lund) (013030000), Molecular Medicine (013031200)
- id
- c0d850f7-9562-49f8-92ab-b11dd62228fb (old id 1582554)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/20201092?dopt=Abstract
- date added to LUP
- 2016-04-04 08:54:04
- date last changed
- 2024-01-29 02:53:00
@article{c0d850f7-9562-49f8-92ab-b11dd62228fb, abstract = {{The cell cycle regulating protein p27(Kip1) (p27) has dual roles by acting as both a cdk-inhibitor and as an assembly factor for different cdk-complexes. Loss of p27 has been linked to malignant features in tumours, however the exact role of p27 deregulation in breast cancer regarding prognostic and treatment predictive information has not been fully clarified. We have evaluated p27 expression in 328 primary, stage II breast cancers from premenopausal patients who had been randomised to either tamoxifen treatment or no adjuvant treatment after surgery. p27 was associated with the oestrogen receptor (ER) and cyclin D1, and p27 downregulation was associated with high proliferation. There was no association between recurrence-free-survival (RFS) and p27 (HR=0.800, 95%CI 0.523-1.222, p=0.300), indicating that p27 is not a prognostic marker. The predictive value of p27 was analysed by comparing RFS in tamoxifen treated and untreated patients in subgroups of low and high p27 expression (HR=0.747, 95%CI 0.335-1.664, p=0.474 and HR=0.401, 95%CI 0.240-0.670, p<0.001, respectively). Only patients with p27 high tumours benefited from tamoxifen (multivariate interaction analysis p=0.034). Our study suggests that p27 downregulation is associated with tamoxifen resistance in premenopausal breast cancer but is not linked to impaired prognosis. (c) 2010 UICC.}}, author = {{Stendahl, Maria and Björner, Sofie and Wigerup, Caroline and Jirström, Karin and Jönsson, Per-Ebbe and Stål, Olle and Landberg, Göran}}, issn = {{0020-7136}}, language = {{eng}}, pages = {{2851--2858}}, publisher = {{John Wiley & Sons Inc.}}, series = {{International Journal of Cancer}}, title = {{p27(Kip1) is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients.}}, url = {{http://dx.doi.org/10.1002/ijc.25297}}, doi = {{10.1002/ijc.25297}}, volume = {{Apr 7}}, year = {{2010}}, }